Ketoacidosis with SGLT-2 Inhibitor and Ketogenic Diet: A Case Study

Mercedez Bernard, D.O., Karen Schafer, D.O.

Abstract


This case study illustrates the importance of obtaining dietary history and supplying dietary education for patients on sodium-glucose cotransporter 2 (SGLT2) inhibitors. In this case, the presumed diagnosis of pure diabetic ketoacidosis is confounded by the persistence of anion gap metabolic acidosis despite correction of glucose and electrolyte abnormalities. Only after obtaining the dietary history could the etiology for the patient’s persistent ketoacidosis be elicited. Frank discussion with the patient regarding his dietary intake and additional diabetic education allowed shared decision making for the physician and patient regarding medication regime. The patient had successful weight loss and improved glucose control while on a low–carbohydrate diet. Due to his reluctance to discontinue the low-carbohydrate diet, SGLT2 inhibitors were discontinued. SGLT2 inhibitors have many benefits for diabetic patients and have been a successful adjunct to the treatment of diabetes; however, patient selection and dietary education when initiating these medications is imperative.

Keywords


SGLT2 Inhibitors; ketoacidosis; ketogenic diets; low carbohydrate diets; diabetic ketoacidosis

Full Text:

HTML PDF

References


Canadian Diabetes Association. Table 1. Antihyperglycemic agents for use in type 2 diabetes. April 2016. http://guidelines.diabetes.ca/cdacpg_resources/Ch13_Table1_Antihyperglycemic_agents_type_2_2016.pdf.

Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach. Diabetes Care 2015;38:140-9.

Zinman B, Wanner C, Lachen J, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, N Engl J Med 2015;373:2117-28. DOI: 10.1056/NEJMoa1504720

Neal B, Perkovic V, Mahaffey K, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes, N Engl J Med 2017;377:644-57. DOI: 10.1056/NEJMoa1611925

Cherney D, Perkins B, Soleymanlou N, et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients with Type 1 Diabetes Mellitus, Circulation.2014;129:587-597

FDA. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Last updated January 2016. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm.

FDA. FDA drug safety communication. FDA confirms increased risk of leg and foot amputations with the diabetes medication canagliflozin (Invokana, Invokamet, Invokamet XR). May 16, 2017. https://www.fda.gov/Drugs/DrugSafety/ucm557507.htm.

Shah Pankaj, Isley William L: Ketoacidosis during a Low-Carbohydrate Diet. NEJM 2006, 354(I):97-98.

Chalasani Swapna, Fischer Jacqueline: South Beach Diet associated ketoacidosis: a case report, Journal of Medical Case Reports 20008, 2:45. DOI:10.1186/1752-1947-2-45.

Tsuh-Yin C, Smith W, Rosenstock J, et al. A life-threatening complication of Atkins diet. Lancet 2006; 367-958.

Taylor Simeon I, Blau Jenny E, Rother Kristina I: SGLT2 Inhibitors May Predispose to Ketoacidosis. The Journal of Clinical Endocrinology and Metabolism 100.8 (2015):2849-852. DOI: 10.1210/jc.2015-1884.

Westman E, Yancy W Jr, Mavropoulos J, et al. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. Nutrition & Metabolism 2008, 5:36 doi:10.1186/1743-7075-5-36.


Refbacks

  • There are currently no refbacks.